Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy
Our findings suggest neoadjuvant immuno-chemotherapy improves prognosis for stage III NSCLC patients and effectively reduces tumor volume and organ-at-risk radiation exposure, warranting further phase III trials.
Authors
- Hao Zhou (ORCID: https://orcid.org/0000-0002-5012-7849)
- Liang Jiang (ORCID: https://orcid.org/0000-0001-6448-4479)
- Zewen Song (ORCID: https://orcid.org/0000-0002-9685-0725)
- Hexin Duan
- Weiwei Liang (ORCID: https://orcid.org/0000-0002-3637-4667)
- Xi Zhang
- Hao Hu
- Xu Tian
- Yechen Ma
- Wenxin Ding
Institutions
- Central South University (CN)
- Jishou University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1016/j.tranon.2025.102394
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04